HER2 Mutation Detection Kit
Qualitative detection of Detection of five mutations in HER2 gene
HER2 mutations in exons 19~20, have been identified in approximately 2~4%of non–small-cell lung cancers (NSCLC). HER2 mutations appear to be found more commonly in never smokers with adenocarcinoma histology. The most common mutation is an in-frame insertion in exon 20. These insertions cause activation of downstream HER2-pathway components such as AKT and MEK. Drugs targeting HER2 include afatinib, traztuzumab, lapatinib, pertuzumab, neratinib and T-DMI. A recent study by Mazieres highlighted the importance of screening for HER2 mutations in NSCLC and suggests that HER2-positive patients may be responsive to HER2-targeted therapy.
The kit uses novel, proprietary primers and probes in a real-time PCR assay to detect 13 HER2 mutations in human genomic DNA. The mutant HER2 gene is amplified by the specific primers, and detected by the fluorescent probes.
To order, please contact firstname.lastname@example.org.
|Product Name||Type||Size (test/kit)||Storage||Cat. No.|
|AmoyDx® HER2 Mutation Detection Kit||Bulk||24||-20±5℃||8.01.26801X024H|
1. Li, Xuefei, et al. "Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China." Bmc Cancer 16.1 (2016): 828.